Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT07216911 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Evaluating the Impact of Psychotherapeutic Advertising Claims on Cannabis Purchasing

StatusActive, Not Recruiting
PhaseNot applicable
Started
View on ClinicalTrials.gov ↗

Record History

  1. Enrollment closed, study ongoing Primary completion date changed from estimate of Jun 30, 2026 to Jul 6, 2026 · Site details revisedv4 Show 2 more changesShow less
    • Primary completion date changed from estimate of Jun 30, 2026 to Jul 6, 2026
    • Site details revised
  2. Recruitment opened Completion pushed from Sep 30, 2026 to Jun 30, 2027 · Study site revisedv3 Show 2 more changesShow less
    • Completion pushed from Sep 30, 2026 to Jun 30, 2027
    • Study site revised

    See this version in full on ClinicalTrials.gov ↗

  3. Start date: Jan 30, 2026 to Apr 15, 2026 Primary completion date: May 30, 2026 to Jun 30, 2026 · Completion date: Jul 31, 2026 to Sep 30, 2026v2 Show 2 more changesShow less
    • Primary completion date: May 30, 2026 to Jun 30, 2026
    • Completion date: Jul 31, 2026 to Sep 30, 2026
  4. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
Trustees of Dartmouth College
25 trials monitored
See 2 trials at risk
Depression
2,998 trials monitored
See 166 trials at risk
Anxiety
2,264 trials monitored
See 97 trials at risk
In the U.S., legal cannabis is frequently advertised as an effective treatment for mental health problems such as anxiety and depression-particularly online. States that have legalized cannabis have not implemented regulations to address this type of advertising. This project aims to investigate the influence of psychotherapeutic advertising claims (PAC) and mental health warning labels (WL) on online cannabis purchasing behaviors among light-to-moderate cannabis users with symptoms of depression and/or anxiety. The specific aims are to determine whether PAC increases cannabis purchasing intentions and whether a mental health WL can mitigate this effect. A realistic online cannabis shopping experience will be simulated using the digital Platform for Online Evaluation of Marijuana Marketing and Sales (POEMMS). The study will employ a between-subjects experimental design by randomizing 2,000 participants to one of four online stores that vary in PAC and WL content: (1) a control claims (CC)-only store, (2) a PAC store, (3) a WL store, and (4) a PAC + WL store. Participants will browse and select items as if making real purchases. Analyses will examine three primary outcomes to determine the influence of PAC and WL on purchasing behaviors: (1) total milligrams of THC purchased, (2) average potency (%THC) of products, and (3) overall number of products purchased. The long-term objective is to inform evidence-based cannabis policy and regulatory strategies by understanding the impact of cannabis marketing on vulnerable populations. This research is relevant to public health by addressing the potential risks associated with misleading cannabis marketing, which may lead to increased use and exacerbation of mental health symptoms among individuals with depression and anxiety. The project leverages a multidisciplinary team with expertise in addiction, mental health, epidemiology, and digital health technology. The findings have the potential to inform the development of targeted interventions and policies to reduce harms associated with cannabis advertising-ultimately contributing to better health outcomes and more effective regulation.
Trial Details
NCT Number NCT07216911
Lead Sponsor Trustees of Dartmouth College
Collaborators: National Institute on Drug Abuse (NIDA)
Conditions Anxiety, Depression, Cannabis Use
Enrollment 2,000 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov